Research & Development

Regenxbio, AbbVie close license and collaboration deal to develop RGX-314

Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314.

Dunad, Novartis partner to develop oral protein degrader therapies

Dunad Therapeutics and Novartis have signed a strategic collaboration and license agreement to develop next generation targeted protein degrader therapies.

Synthekine, Merck partner to develop new cytokine-based therapies

Synthekine and Merck have signed a global research collaboration and license agreement to develop novel cytokine-based therapeutics.

Gilead, Merck to study combination therapy for breast cancer

Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC).

Immunai raises funding to expand drug actuary platform

Biotech company Immunai has raised $215m in Series B funding round to accelerate the development of its immune-first drug actuary platform.

Takeda to buy GammaDelta to accelerate allogeneic cell therapies development

Takeda Pharmaceutical has exercised its option to acquire GammaDelta Therapeutics to accelerate development of allogeneic γδT cell therapies to address solid tumours.

Teva, Modag to develop drug candidates for neurodegenerative disease

Teva Pharmaceutical has partnered with Modag for the development and licensing of the latter's drug candidates, anle138b and sery433, for neurodegenerative disease.

Vertex, Mammoth partner to develop in vivo gene-editing therapies

Vertex Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo gene-editing therapies for two genetic diseases.

EMA’s CHMP begins rolling review of molnupiravir to treat Covid-19 in adults

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of molnupiravir (MK-4482 and EIDD-2801), an investigational oral antiviral medicine, to treat adult patients with Covid-19.